Alemtuzumab
- PDF / 169,410 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 86 Downloads / 140 Views
1 S
Alemtuzumab
Autoimmune thyroid disease presenting as primary hypothyroidism, thyroiditis and hyperthyroidism: 4 case reports A retrospective analysis conducted at a tertiary referral center (United Kingdom) involving 126 patients with relapsing-remitting multiple sclerosis treated with alemtuzumab between 2012 and 2017, four patients [ages and sexes not stated] were described, who developed autoimmune thyroid disease (AITD) presenting as primary hypothyroidism (2 patients), thyroiditis (1 patient) and hyperthyroidism (1 patient) during treatment with alemtuzumab for relapsing-remitting multiple sclerosis. The patients, who had relapsing-remitting multiple sclerosis, received treatment with alemtuzumab [routes and dosages not stated]. Subsequently, two of the patients [thyroid peroxidase antibody positive patient (n=1) and thyrotropin receptor antibody positive patient (n=1)] developed AITD presenting as primary hypothyroidism. The remaining two patients developed AITD presenting as thyroiditis (n=1) and hyperthyroidism of unknown aetiology (n=1), respectively [durations of treatments to reactions onsets and outcomes not stated]. Sovetkina A, et al. Development of autoimmune thyroid disease in multiple sclerosis patients post-alemtuzumab improves treatment response. Journal of Clinical Endocrinology and Metabolism 105: E3392-E3399, No. 9, Sep 2020. Available from: URL: http://doi.org/10.1210/clinem/dgaa453
0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803517570
Reactions 28 Nov 2020 No. 1832
Data Loading...
